Wolfram Ruf Selected Research

PAR-1 Receptor

12/2020	Platelet-derived calpain cleaves the endothelial protease-activated receptor 1 to induce vascular inflammation in diabetes.
4/2012	Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease-activated receptor 2 cofactors that enhance infection.
3/2009	Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality.
6/2007	Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis.
7/2004	Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfram Ruf Research Topics

Disease

51	Neoplasms (Cancer) 05/2022 - 09/2002
39	Inflammation (Inflammations) 12/2022 - 04/2003
28	Thrombosis (Thrombus) 05/2022 - 08/2005
12	Neoplasm Metastasis (Metastasis) 01/2020 - 12/2003
11	Sepsis (Septicemia) 01/2020 - 06/2002
10	Breast Neoplasms (Breast Cancer) 01/2015 - 01/2008
8	Hemorrhage 01/2022 - 12/2009
8	Infections 10/2021 - 02/2008
7	Atherosclerosis 11/2020 - 10/2004
6	Hypoxia (Hypoxemia) 07/2019 - 10/2006
6	Endotoxemia 11/2015 - 01/2003
4	COVID-19 01/2022 - 01/2021
4	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021 - 01/2017
4	Obesity 06/2019 - 10/2011
3	Hemophilia A (Haemophilia) 01/2022 - 11/2017
3	Pregnancy Complications 12/2021 - 10/2008
3	Melanoma (Melanoma, Malignant) 10/2021 - 09/2003
3	Atherosclerotic Plaque (Atheroma) 11/2020 - 08/2005
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020 - 01/2017
3	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 10/2019 - 10/2008
3	Carcinoma (Carcinomatosis) 07/2019 - 01/2014
3	Adenocarcinoma 01/2014 - 09/2008
2	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022 - 11/2021
2	Thromboembolism 05/2022 - 11/2021
2	Fibrosis (Cirrhosis) 01/2022 - 01/2020
2	Vascular System Injuries 01/2021 - 10/2006
2	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 08/2011
2	Pneumonia (Pneumonitis) 01/2021 - 02/2008
2	Cardiovascular Diseases (Cardiovascular Disease) 07/2020 - 01/2017
2	Type 2 Diabetes Mellitus (MODY) 01/2020 - 01/2020
2	Hypertension (High Blood Pressure) 01/2020 - 01/2017
2	Ovarian Neoplasms (Ovarian Cancer) 07/2019 - 01/2016
2	Insulin Resistance 06/2019 - 10/2011
2	Necrosis 01/2017 - 09/2015
2	Triple Negative Breast Neoplasms 05/2014 - 01/2013
2	Carcinogenesis 07/2012 - 08/2005

Drug/Important Bio-Agent (IBA)

70	Thromboplastin (Tissue Factor)IBA 05/2022 - 01/2003
21	Proteinase-Activated ReceptorsIBA 01/2022 - 04/2003
20	Peptide Hydrolases (Proteases)FDA Link 06/2019 - 01/2003
17	Thrombin FDA Link 01/2022 - 04/2003
15	AnticoagulantsIBA 01/2022 - 04/2003
13	Endothelial Protein C ReceptorIBA 01/2022 - 06/2002
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2003
12	Hemostatics (Antihemorrhagics)IBA 08/2021 - 01/2007
11	PAR-2 ReceptorIBA 01/2019 - 09/2006
9	Protein CIBA 01/2020 - 06/2002
9	IntegrinsIBA 01/2018 - 07/2004
7	GTP-Binding Proteins (G-Protein)IBA 06/2019 - 09/2004
7	FibrinIBA 06/2019 - 04/2006
6	CytokinesIBA 01/2022 - 01/2007
6	Blood Coagulation Factors (Coagulation Factor)IBA 11/2021 - 10/2006
6	CoagulantsIBA 08/2021 - 06/2002
6	Factor VIIa (Activated Factor VII)IBA 01/2021 - 04/2006
6	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2010 - 04/2006
5	AntibodiesIBA 01/2022 - 07/2004
5	PAR-1 ReceptorIBA 12/2020 - 07/2004
5	Complement System Proteins (Complement)IBA 10/2019 - 10/2004
5	Serine Proteases (Serine Protease)IBA 01/2012 - 07/2004
4	fibrin fragment D (D-dimer)IBA 01/2022 - 01/2020
4	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2022 - 01/2015
4	Antiphospholipid AntibodiesIBA 12/2021 - 10/2008
4	Factor VII (Proconvertin)IBA 07/2019 - 10/2006
4	LipopolysaccharidesIBA 04/2015 - 06/2007
4	Thrombin Receptors (Thrombin Receptor)IBA 04/2010 - 06/2002
3	AntigensIBA 05/2022 - 08/2008
3	ChemokinesIBA 01/2022 - 09/2008
3	LipidsIBA 01/2021 - 01/2018
3	Factor X (Stuart Factor)IBA 01/2021 - 01/2019
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 01/2017
3	Angiotensin IIIBA 07/2020 - 01/2017
3	Blocking AntibodiesIBA 01/2016 - 01/2013
3	Peptides (Polypeptides)IBA 01/2012 - 07/2004
2	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 12/2022 - 04/2008
2	Pharmaceutical PreparationsIBA 01/2022 - 11/2013
2	bis(monoacylglyceryl)phosphateIBA 12/2021 - 01/2021
2	Factor Xa InhibitorsIBA 10/2021 - 09/2020
2	RivaroxabanIBA 10/2021 - 01/2019
2	Factor Xa (Coagulation Factor Xa)IBA 10/2021 - 10/2006
2	C-Reactive ProteinIBA 01/2021 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2021 - 01/2018
2	Protein Isoforms (Isoforms)IBA 01/2020 - 07/2013
2	Transcription Factors (Transcription Factor)IBA 07/2019 - 07/2012
2	ElementsIBA 07/2019 - 12/2009
2	ChromatinIBA 07/2019 - 10/2006
2	Plasminogen Activators (Plasminogen Activator)IBA 06/2019 - 11/2013
2	Antiviral Agents (Antivirals)IBA 01/2019 - 09/2004
2	recombinant FVIIa (rFVIIa)FDA Link 07/2018 - 11/2017
2	Protein Disulfide-IsomerasesIBA 01/2018 - 05/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2017 - 05/2010
2	Small Interfering RNA (siRNA)IBA 01/2016 - 09/2008
2	Cell Surface ReceptorsIBA 04/2015 - 03/2009
2	Adenosine Triphosphate (ATP)IBA 04/2015 - 04/2014
2	Purinergic P2X7 ReceptorsIBA 04/2014 - 07/2011
2	Messenger RNA (mRNA)IBA 01/2014 - 10/2006
2	TrypsinIBA 01/2012 - 07/2004
2	activated protein C receptorIBA 09/2010 - 01/2003

Therapy/Procedure

21	Therapeutics 01/2022 - 04/2003
4	Drug Therapy (Chemotherapy) 01/2022 - 09/2015
3	Ligation 01/2022 - 09/2008
2	Immunotherapy 01/2020 - 01/2019